Atomoxetine HCl , ≥98% , 82248-59-7

Synonym(s):
(R)-N-Methyl-γ-(2-methyl-phenoxy)benzenepropanamine hydrochloride;(R)-Tomoxetine hydrochloride;Atomoxetine hydrochloride

CAS NO.：82248-59-7

Empirical Formula: C17H22ClNO

Molecular Weight: 291.82

MDL number: MFCD06410992

EINECS: 629-925-3

PRODUCT Properties

• Melting point: 167-169°C
• alpha: D25 -38.01°; 36525 -177.26° (c = 1 in methanol); D23 -41.37° (c = 1.02 in methanol); D25 -40.3° (c = 0.94 in ethanol)
• Flash point: 9℃
• storage temp.: 2-8°C
• solubility: soluble in Methanol
• form: solid
• pka: 10.13(at 25℃)
• color: White to Almost white
• optical activity: -37.10°(C=0.01g/mL, MEOH, 589nm)
• Water Solubility: Soluble to 50 mM in water with gentle warming
• Merck: 14,863
• BCS Class: 1?
• InChI: InChI=1/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/s3
• InChIKey: LUCXVPAZUDVVBT-UNTBIKODSA-N
• SMILES: O([C@H](CCNC)C1C=CC=CC=1)C1=CC=CC=C1C.Cl |&1:1,r|
• CAS DataBase Reference: 82248-59-7(CAS DataBase Reference)

Description and Uses

Atomoxetine is the first non-stimulant marketed for the treatment of attention deficit hyperactivity disorder (ADHD). It is the R-stereoisomer of the racemate tomoxetine and is a selective and potent norepinephrine uptake inhibitor (K_i=0.7–1.9 nM) that is devoid of binding to monoamine receptor. It also has little effect on dopamine and serotonin reuptake or acetylcholine, H1 histamine, alpha1 or alpha1-adrenergic or dopamine receptors. It is prepared from racemic 1-phenylbut-3-en-1-ol via a selective enzymatic acylation leaving the desired S-stereoisomer as the alcohol. This alcohol is converted via a Mitsunobu reaction with ortho-cresol to the corresponding ether with isomeric R-configuration. Ozonolysis and reduction steps provided the terminal alcohol that is mesylated and displaced with methylamine. Its selectivity for norepinephrine relative to dopamine inhibition was demonstrated in vivo preclinically. In a two-lever (two condition) discriminative stimulus effect study in squirrel monkeys, tomoxetine and other norepinephrine uptake inhibitors substituted for cocaine under low-dose training conditions, whereas dopamine uptake inhibitors substituted for cocaine in both low and high-dose conditions. In clinical ADHD studies in adolescents, it was significantly different from placebo in 1.2 and 1.8 mpk/day dosing. In the clinical study in adults using the CAARS scale a 95 mg/day dose provided greater than 30% improvement in total scores. Atomoxetine is about 63% orally bioavailable, is highly protein bound (98%, primarily to albumin) and has a half-life of about 5.2 h. It is metabolized by CYP2D6 resulting in differential clearance for poor metabolizers (halflife of 19 h with a 10 times higher AUC) relative to extensive metabolizers. The total daily dose for children, adolescents and adults is a maximum of 100 mg/day. Common side effects in children and adults include nausea, decreased appetite, and dizziness. Adults may also have insomnia.

(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:

• to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
• to study its effects on set shifting in rats
• to study its effects on rat brain as a result of its long-term use

Safety

• Symbol(GHS): GHS02,GHS06,GHS08
• Signal word: Danger
• Hazard statements: H225-H301+H311+H331-H370
• Precautionary statements: P210-P260-P280-P301+P310-P311
• Hazard Codes: F,T
• Risk Statements: 11-23/24/25-39/23/24/25
• Safety Statements: 22-24/25-45-36/37-16-7
• RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany: 3
• HS Code: 29221990